Variant not associated with CLL, AIHA, or ITP in certain patients

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or autoimmune hematologic disorders in patients from the Republic of Macedonia. Past studies have shown an association between the PTPN22 R620W variant and both CLL and autoimmune diseases in patients from... [Read Article]
Print Friendly, PDF & Email

System may better predict thrombosis in lymphoma

Print Friendly, PDF & Email


Audience at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice
An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to researchers. The revised scoring system, ThroLy, proved more effective than other systems for predicting thromboembolic events in lymphoma patients. Researchers found the updated ThroLy had... [Read Article]
Print Friendly, PDF & Email

Emicizumab now also approved for hemophilia A without inhibitors

Print Friendly, PDF & Email


Emicizumab (Hemlibra)
Photo from Business Wire
The U.S. Food and Drug Administration (FDA) approved emicizumab-kxwh (Hemlibra) for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients, including newborns, with hemophilia A with or without factor VIII (FVIII) inhibitors. It was first approved in 2017 for hemophilia A patients with FVIII... [Read Article]
Print Friendly, PDF & Email

CHMP recommends factor VIII therapy for hemophilia A

Print Friendly, PDF & Email


U.S. version of damoctocog alfa pegol (Jivi®)
Photo from Bayer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for damoctocog alfa pegol, a recombinant human factor VIII therapy. Bayer is seeking European marketing authorization for damoctocog alfa pegol (formerly BAY94-9027), for the treatment and prophylaxis of... [Read Article]
Print Friendly, PDF & Email

Caplacizumab approved to treat aTTP

Print Friendly, PDF & Email


Vials and a syringe
The European Commission has granted marketing authorization for caplacizumab (Cablivi™), a humanized bivalent nanobody that inhibits the interaction between von Willebrand factor and platelets. Caplacizumab is now approved to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP) in all member countries of the European Union as well as Norway, Iceland, and... [Read Article]
Print Friendly, PDF & Email

Rivaroxaban has ‘favorable’ benefit-risk profile

Print Friendly, PDF & Email


Rivaroxaban (Xarelto)
Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended venous thromboembolism (VTE) treatment when compared to aspirin, according to investigators. The team found the combined outcome of recurrent VTE and major bleeding was less likely to occur in patients treated with rivaroxaban at 20 mg or 10 mg than in patients... [Read Article]
Print Friendly, PDF & Email

Factor VIII product approved for hemophilia A

Print Friendly, PDF & Email


Antihemophilic factor
(recombinant)
PEGylated-aucl (Jivi®)
Photo from Bayer
The US Food and Drug Administration (FDA) has approved Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) for the treatment of hemophilia A. Jivi (formerly BAY94-9027) is a DNA-derived, factor VIII concentrate approved for use in previously treated adults and adolescents (age 12 and older) with hemophilia A. The product... [Read Article]
Print Friendly, PDF & Email

A new standard of care in hemophilia A?

Print Friendly, PDF & Email


Emicizumab (Hemlibra)
Photo from Business Wire
Results of a phase 3 trial showed that prophylaxis with emicizumab significantly reduced bleeds, compared to no prophylaxis, in patients with hemophilia A without inhibitors. Emicizumab also reduced bleeds when compared to prior factor VIII prophylaxis. The most common adverse events (AEs) in this trial were injection site reactions,... [Read Article]
Print Friendly, PDF & Email